- Nine-month sales reached €399 million, an increase of 3.9% on a reported basis and 5.4% at constant exchange rates.
- Third-quarter sales totaled €139.7 million, up 10.4% on a reported basis and 9.6% at constant exchange rates.
- Essentials products generated €259 million in nine-month sales, accounting for 64.9% of total sales, compared with 63.6% a year earlier.
- Regional growth at constant exchange rates for the first nine months included increases of 12.4% in the United States, 4.6% in Europe and 4.6% in Asia-Pacific/Rest of the World.
- Product line simplification reduced nine-month sales by €3.7 million, while currency movements had a negative impact of €6.1 million.
Vetoquinol reported sales of €399 million for the first nine months of 2026, compared with €384.2 million during the same period in 2025. The results represent growth of 3.9% on a reported basis and 5.4% at constant exchange rates.
Excluding the impact of its complementary product line simplification program and adjusting for currency movements, the company reported year-to-date sales growth of 6.6% at constant exchange rates.
The nine-month results included a €3.7 million reduction associated with product line simplification, compared with a €7.7 million impact through September 2025, as well as a negative currency effect of €6.1 million.
Third-Quarter Sales Increase 10.4%
Vetoquinol generated €139.7 million in third-quarter sales, compared with €126.6 million in the third quarter of 2025. Sales increased 10.4% on a reported basis and 9.6% at constant exchange rates.
The quarter benefited from a favorable currency impact of €1 million from the United States and the Americas excluding the U.S.
Growth was driven by the Essentials segment, which increased 13.9% on a reported basis and 12.9% at constant exchange rates during the quarter.
The results also included a €0.6 million negative impact from the simplification of complementary product lines.
According to the company, third-quarter performance continued the growth momentum observed during the first half of the year and benefited from a favorable comparison with the third quarter of 2025.
Essentials Products Account for Nearly 65% of Sales
Vetoquinol’s Essentials segment generated €259 million in sales during the first nine months of 2026, representing growth of 6.0% on a reported basis and 6.7% at constant exchange rates.
Essentials products accounted for 64.9% of total company sales through September 2026, compared with 63.6% during the corresponding period in 2025.
The Essentials portfolio includes veterinary medicines and non-medicated products for companion and farm animals. These products are designed to address veterinarians’ daily needs and are intended for worldwide distribution.
U.S. Leads Nine-Month Regional Growth
At constant exchange rates, Vetoquinol reported sales growth across three of its four strategic geographic regions during the first nine months of 2026.
| Region | Nine-month sales | Constant-currency growth |
|---|---|---|
| Europe | €197.8M | +4.6% |
| United States | €86.9M | +12.4% |
| Asia-Pacific / Rest of World | €60.6M | +4.6% |
| Americas excluding U.S. | €53.7M | −0.9% |
| Total | €399.0M | +5.4% |
During the third quarter alone, sales at constant exchange rates increased 8% in Europe, 11% in the United States and 23% in Asia-Pacific/Rest of the World. Sales declined 1% in the Americas excluding the United States.
Quarterly Sales Performance
Vetoquinol reported the following quarterly sales results for 2026 compared with the corresponding periods in 2025.
| Period | 2026 sales | Reported growth | Constant-currency growth |
|---|---|---|---|
| Q1 | €125.0M | −4.3% | −0.3% |
| Q2 | €134.3M | +5.7% | +7.2% |
| Q3 | €139.7M | +10.4% | +9.6% |
| Nine months | €399.0M | +3.9% | +5.4% |
Next Financial Update
Vetoquinol is scheduled to release its full-year 2026 sales results on January 14, 2027, after market close.
The company, founded in 1933, develops and markets veterinary medicines and non-medicated products for companion animals, including dogs and cats, and farm animals, including cattle and pigs. Vetoquinol operates across Europe, the Americas and Asia-Pacific.
As of June 30, 2026, Vetoquinol employed 2,526 people. The company has been listed on Euronext Paris since 2006 under the ticker symbol VETO.
Information sourced from Vetoquinol’s company press release.
